Whalesbook
Health Canada's approval of Dr. Reddy's generic semaglutide injection marks a major turning point for the lucrative GLP-1 drug market. This development signals that these popular therapies, which have fueled massive growth and high valuations for pharmaceutical giants, are increasingly becoming standard, lower-cost medications.
Dr. Reddy's Laboratories has secured Canada's first generic approval for semaglutide, the key ingredient in Novo Nordisk's highly successful Ozempic and Wegovy drugs. This approval, achieved quickly within Health Canada's typical 180-day review window, allows Dr. Reddy's to capitalize as patents on the original drugs expire. In Canada, generic drugs typically cost 45% to 90% less than their branded counterparts. Monthly treatment costs could drop significantly, potentially as low as $14 globally. This swift approval process for Dr. Reddy's may set a precedent, potentially speeding up the arrival of other generic competitors and further squeezing profits for all GLP-1 drugs.
The global GLP-1 market, estimated at $53.46 billion in 2024 and projected to reach $156.71 billion by 2030, is largely controlled by Novo Nordisk and Eli Lilly, holding over 80% of the market. Eli Lilly's drug tirzepatide (Mounjaro/Zepbound), which targets GLP-1 and GIP receptors, is gaining strong traction and is expected to contribute significantly to its 2026 revenue. Novo Nordisk, though a market leader, is facing increasing challenges. The company anticipates a revenue drop of 5% to 13% in 2026 due to U.S. pricing pressures and rising competition. Analysts have given Novo Nordisk mixed ratings, with concerns growing about patent expirations for semaglutide around 2031-2032 and a recent drop in its stock price of about 75% from its high. Dr. Reddy's, with a market value around $11.3 billion and a P/E ratio of about 17.2, is set to gain from this market change. However, it faces strong competition, as Health Canada is reviewing at least eight other generic semaglutide applications, pointing to rapidly increasing competitive pressures.
The fast shift of GLP-1 drugs towards becoming standard, lower-cost generics poses a major threat to the high profits drugmakers have enjoyed. Novo Nordisk's recent forecast of its first annual sales decrease in nine years highlights this risk. The company's stock has already fallen sharply, as investors worry about pricing pressures and the impact of generic competition. Competition is also growing in other ways. Eli Lilly's tirzepatide has shown better weight loss results than semaglutide in some studies. Additionally, new oral GLP-1 drugs, like Lilly's Foundayo, could challenge the market for injectable versions. U.S. government actions, such as potential price negotiations, are also pushing drug prices down overall. Analyst views on Dr. Reddy's are mixed. While some anticipate gains, others, like Citi, rate the stock as a Sell. They caution that recent stock price increases might overestimate the benefits given the expected fierce competition, projecting only $50 million in revenue from Canadian generics by 2028 for Dr. Reddy's, competing against five other companies.
The approval of generic semaglutide in Canada is just the beginning of a significant market shift. As more generic competitors launch worldwide, the financial model for GLP-1 treatments will change. This could affect how much drug companies invest in research and development for future new drugs. Although the total GLP-1 market is expected to grow substantially, reaching $190 billion by 2035, the price per drug unit will likely decrease. The industry must navigate increasing pressure on profits from both regulations and intense competition, requiring companies to rethink their strategies and pricing to remain profitable as GLP-1 drugs become more affordable.